Skip to main content

Market Overview

Molecular Partners/Novartis's COVID-19 Antiviral Therapy Shows Encouraging Action Early-Stage Study


Molecular Partners AG (OTCMKTS: MLLCF) and its collaborator Novartis AG (NYSE: NVShave announced initial results from the ongoing Phase 1 study of its COVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers.

  • In two cohorts of a single infusion of either 3mg or 9mg per kilogram body weight dosing, ensovibep was seen to be safe and well-tolerated.
  • No significant adverse events were reported.
  • Preliminary results showed extended exposure of MP0420 in serum, with a half-life of 2-3 weeks.
  • The company plans to initiate Phase 2/3 global registration study in the second quarter of this year.
  • The third cohort in this Phase 1 study, at a 20mg per kilogram dose level, has been planned. The cohort has not been enrolled due to the pandemic-related restrictions, with possible enrollment to start in the coming weeks.
  • The companies have already identified the therapeutic dose levels, which will be investigated in the upcoming clinical studies below the 20mg per kilogram level.
  • Price Action: NVS shares are down 0.4% at $83.37, while MLLCF is up 1.4% at $21.54 in premarket trading on the last check Tuesday.

Related Articles (NVS + MLLCF)

View Comments and Join the Discussion!

Posted-In: Covid-19 Phase 1 TrialBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at